233 related articles for article (PubMed ID: 12517256)
1. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Drucker DJ
Expert Opin Investig Drugs; 2003 Jan; 12(1):87-100. PubMed ID: 12517256
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
Mentlein R
Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes.
Sebokova E; Christ AD; Boehringer M; Mizrahi J
Curr Top Med Chem; 2007; 7(6):547-55. PubMed ID: 17352676
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
7. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Expert Opin Emerg Drugs; 2006 Sep; 11(3):525-39. PubMed ID: 16939389
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Flatt PR; Bailey CJ; Green BD
Front Biosci; 2008 May; 13():3648-60. PubMed ID: 18508462
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon CF; Ahrén B; Holst JJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1091-102. PubMed ID: 15330741
[TBL] [Abstract][Full Text] [Related]
13. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
15. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
16. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
17. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
19. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.
Pauly RP; Demuth HU; Rosche F; Schmidt J; White HA; Lynn F; McIntosh CH; Pederson RA
Metabolism; 1999 Mar; 48(3):385-9. PubMed ID: 10094118
[TBL] [Abstract][Full Text] [Related]
20. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
Deacon CF
Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
